...azeliragon ( TTP488 ; PF-04494700 ; PF-4494700 ) in Phase III testing for Alzheimer's disease. Dynamis Therapeutics Inc....

...pretreatment. Next steps include developing antibodies against the specific RAGE domains involved in mediating metastasis. Dynamis Therapeutics Inc.'s...

...Advanced Glycations End (RAGE) products inhibitor lived an average of 256 days longer than controls. Dynamis Therapeutics Inc....

...kidney and retina vs. age-matched controls. The RAGE inhibitor was orally administered for 32 weeks. Dynamis Therapeutics Inc....

...use its Genes to Leads lead identification technology to screen candidates against a target from Dynamis...
...receive upfront payments and is eligible for milestones. Cengent Therapeutics Inc. , San Diego, Calif. Dynamis Therapeutics Inc....

...use its Genes to Leads lead identification technology to screen candidates against a target from Dynamis...

...Dynamis and the center formed a joint venture to develop Dynamis's Dyn 12 small molecule inhibitor...
...enzyme involved in the formation of 3-deoxyglucosone (3DG), which is associated with complications of diabetes. Dynamis...
...compound to prevent diabetes-related diseases and blindness. The center licensed Asian rights to the compound. Dynamis Therapeutics Inc....

...Dynamis and the Development Center for Biotechnology (Taipei, Taiwan) formed a joint venture to develop Dynamis's...
...enzyme involved in the formation of 3-deoxyglucosone (3DG), which is associated with complications of diabetes. Dynamis...

...involved in the development of Advanced Glycation End products (AGEs), which cause diabetic kidney disease. Dynamis Therapeutics Inc....